Niagen Bioscience Inc
OCD1
Company Profile
Business description
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Contact
10900 Wilshire Boulevard
Suite 600
Los AngelesCA90024
USAT: +1 310 388-6706
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
117
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
Aussie property manager lifts earnings expectations despite interest rate uncertainty.
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.20 | 66.70 | 0.75% |
| CAC 40 | 8,207.45 | 34.34 | 0.42% |
| DAX 40 | 25,337.88 | 152.99 | 0.61% |
| Dow JONES (US) | 50,461.68 | 118.02 | -0.23% |
| FTSE 100 | 10,477.70 | 13.69 | -0.13% |
| HKSE | 25,301.10 | 298.35 | -1.17% |
| NASDAQ | 26,656.18 | 312.21 | 1.19% |
| Nikkei 225 | 64,999.41 | 3.32 | 0.01% |
| NZX 50 Index | 13,227.81 | 158.07 | 1.21% |
| S&P 500 | 7,519.12 | 45.65 | 0.61% |
| S&P/ASX 200 | 8,717.70 | 65.50 | 0.76% |
| SSE Composite Index | 4,093.73 | 51.65 | -1.25% |